|  |  |
| --- | --- |
| Clone | EP137 |
| Source | Rabbit Monoclonal |
| Cat # | PR248-6ml RTU PR248-3ml RTU  CR248-0.1ml Conc CR248-0.5ml Conc HAR248-6ml RTU HAR248-3ml RTU |
| Regulatory Status | IVD |

FOXP1- (EP137)

**Intended Use:**

This antibody is intended for use to qualitatively identify FOXP1 antigen by light microscopy in formalin fixed, paraffin embedded tissue sections using immunohistochemical detection methodology. Interpretation of any positive or negative staining must be complemented with the evaluation of proper controls and must be made within the context of the patient’s clinical history and other diagnostic tests. A qualified pathologist must perform evaluation of the test.

**Summary and Explanation:**   
  
The FOXP1 protein belongs to a functionally diverse family of winged-helix or forkhead transcription factors that have diverse roles in cellular proliferation, differentiation, and neoplastic transformation. The FOXP1 gene has been mapped to chromosome 3p14.1, a region that commonly shows loss of heterozygosity in a wide range of tumors and is reported to contain a tumor suppressor gene(s).

The FOXP1 protein is widely expressed in normal human tissues. It labels activated B cells in the mantle zone and germinal center of lymphoid tissues. In lymphoid malignancies, FOXP1 protein expression may be found in diffuse large B-cell lymphomas and extranodal marginal zone B-cell lymphomas of mucosa-associated lymphoid tissue (MALT). Strong expression of FOXP1 is associated with poor disease-free survival and transformation to diffuse large B- cell lymphomas.

Recently, studies suggested a role of FOXP1 in the regulation of ER expression. FOXP1 expression is correlated with ER expression and improved survival in breast cancer patients. Nuclear expression of FOXP1 is associated with ER expression, while cytoplasmic expression of FOXP1 is linked to myometrial invasion in endometrial cancer.

**Isotype:** Rabbit IgG

**Immunogen:** A synthetic peptide corresponding to residues of human FOXP1 protein.

**Reagent Provided:**

**Concentrated format:** Antibody to FOXP1 is diluted in antibody diluent, with 1% bovine   
 serum albumin (BSA) and 0.05% sodium azide (NaN3). Recommended   
 dilutions: 1:50 – 1:100.The antibody dilution and protocol may vary depending on   
 the specimen preparation and specific application. Optimal conditions should be   
 determined by individual laboratory.

**Pre-diluted format:** PathnSitu ready to use antibodies are pre tittered to optimal staining   
 conditions. Further dilution may loose the activity and may yield to sub   
 optimal staining.

**Storage Recommendations:** Store at 2°-8°C. Do not use after expiration date provided on the vial.

**Staining Recommendations:   
 Antigen Retrieval Solution:** Use **Tris-EDTA (PathnSitu Cat # PS009)** as antigen retrieval solution   
 Heat Retrieval Method: Retrieve sections under steam pressure for 15min   
 using PathnSitu’s MERS (Multi Epitope Retrieval System) then allow   
 solution to cool for 10 minutes then transfer tissue sections/slides to   
 distilled water.

**Primary Antibody:**  Cover the tissue sections with primary antibody and incubate for 30   
 min at room temperature when used PathnSitu PolyExcel Detection   
 System.

**Detection System:** Refer to PathnSitu PolyExcel detection system protocol or manufacturer’s detection kit staining protocol when used other vendor detection system.

**Cellular Localization:** Nucleus/Cytoplasmic

**Positive Control:** Tonsil, Diffuse Large B-Cell Lymphoma

**Troubleshooting:** Follow the antibody specific protocol recommendations according to data sheet provided. If unusual results occur, contact PathnSitu Technical Support at 040-2701 5544 or techsupport@pathnsitu.com.

**Limitations and Warranty:** There are no warranties, expressed or implied, which extend beyond this   
 description. PathnSitu is not liable for property damage, personal injury, or   
 economic loss caused by this product.

**Bibliography:**  1. Wang B, et al.: J Biol Chem 2003, 278:24259-24268   
 2. Sagaert X, et al.: J Clin Oncol 2006, 24:2490-2497   
 3. Barrans SL, et al.: Blood 2004, 104:2933-2935   
 4. Banham AH, et al.: Clin Cancer Res 2005, 11:1065-1072   
 5. Hans CP, et al.: Blood 2004, 103:275-282   
 6. Goatly A, et al.: Mod Pathol 2008, 21:902-911   
 7. Banham AH, et al.: Cancer Res 2001, 61:8820-8829   
   
**FOXP1, EP137 antibody has been created by Epitomics Inc., using Epitomics’ proprietary rabbit monoclonal antibody technology covered under Patent No.’s 5,675,063 and 7,402,409.**